Global In-Line Blood Monitoring Devices Market - 2025-2033

The global In-line blood monitoring devices market reached US$ 100,630.41 thousand in 2024 and is expected to reach US$ 317,891.08 thousand by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033.

In-line blood monitoring devices are medical instruments used to continuously measure and assess various critical parameters of a patient's blood in real-time, typically during surgical procedures, intensive care or extracorporeal treatments such as cardiopulmonary bypass, dialysis, or ECMO (Extracorporeal Membrane Oxygenation). These devices are integrated directly into the blood circulation pathway, allowing for non-invasive or minimally invasive monitoring without requiring repeated blood sampling.

The demand for In-line blood monitoring devices is experiencing significant growth, which is attributed to factors such as growing surgical procedures requiring extracorporeal circulation and the growing critical cardiovascular procedures such as transplantations. For instance, according to the Mass General Brigham Organization, more than 900,000 cardiac surgeries, including coronary bypass surgeries, are performed in the U.S. every year, with even more taking place throughout the world. Cardiac surgery is performed on the heart and its large blood vessels, including the pulmonary arteries and the aorta.

Additionally, according to ScienceDirect, surgery has recently been recognized as an integral part of national health systems, yet approximately 5 billion people remain without timely access to safe and affordable surgical care when needed. More than 17 million people die of surgically preventable conditions every year, and only 6% of the 313 million surgical interventions taking place every year occur in the poorest one-third of the world's population, in whom the need for surgical care is highest. These rising surgical procedures increase the demand for in-line blood monitoring devices market.

Market Dynamics: Drivers & Restraints

Increasing prevalence of cardiovascular and critical conditions

The increasing prevalence of cardiovascular diseases and critical conditions like sepsis, stroke and respiratory failure is significantly driving the growth of the In-line blood monitoring devices market. These conditions require constant, real-time monitoring of critical blood parameters, such as oxygen levels, blood gases, electrolytes and hemoglobin. In-line blood monitoring devices are critical in providing continuous, non-invasive and accurate assessments to optimize patient care in intensive care units (ICUs), operating rooms and emergency care settings.

For instance, according to the World Health Organization (WHO), Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This rising cardiovascular deaths has spurred the demand for advanced monitoring during high-risk procedures like coronary artery bypass, heart transplants and other cardiovascular surgeries.

In-line blood monitoring devices, particularly in cardiac surgeries, enable real-time tracking of parameters such as blood oxygen saturation, pH levels and carbon dioxide concentrations, essential for managing patient stability during these complex procedures.

The global rise in hypertension and other risk factors for cardiovascular diseases directly correlates to an increasing need for continuous monitoring of blood parameters to prevent complications during treatments or post-surgical recovery.

For instance, according to the World Health Organization, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. An estimated 46% of adults with hypertension are unaware that they have the condition. Less than half of adults (42%) with hypertension are diagnosed and treated. Approximately 1 in 5 adults (21%) with hypertension have it under control.

Complexity of integration with existing systems

The complexity of integration with existing healthcare systems is a key challenge hampering the growth of the global In-line blood monitoring devices market. While these devices offer advanced capabilities for continuous, real-time monitoring, integrating them with hospital information systems (HIS), electronic health records (EHR) and other clinical infrastructure remains a significant hurdle.

Many healthcare facilities still rely on legacy systems that were not designed to interface seamlessly with modern monitoring devices. Older EHR systems or hospital management software often lack compatibility with newer in-line monitoring technologies.

A study by Healthcare IT News highlighted that 80% of healthcare providers still face issues integrating newer diagnostic technologies into their existing infrastructure. In-line blood monitoring devices need to be integrated with existing platforms for data transmission and analysis, but these outdated systems can cause delays, errors or even data loss.

Integrating continuous blood monitoring devices with hospital IT systems raises significant data security and privacy issues. For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records were noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month.

Segment Analysis

The global In-line blood monitoring devices market is segmented based on modality, product, application and region.

Product:

The In-line blood monitoring devices segment is expected to dominate the market

The In-line blood monitoring devices segment is expected to dominate the global market. The In-line blood monitoring devices are crucial for diagnosing various medical conditions, including respiratory failure, metabolic disorders and conditions affecting oxygenation. Healthcare providers often utilize this during surgeries by integrating with heart-lung machines to make timely decisions regarding patient care. By assessing parameters such as partial pressures of oxygen (PaO2), carbon dioxide (PaCO2) and bicarbonate levels, clinicians can determine the adequacy of ventilation and oxygenation, guiding interventions like oxygen therapy or mechanical ventilation.

The companies are developing advanced in-line blood monitoring devices that meet the safety and regulatory standards that are set by the regulatory bodies. For instance, in March 2024, Terumo Cardiovascular received the FDA 510(k) clearance for its next-generation CDI OneView monitoring system. Terumo's CDI systems display patient parameters during cardiopulmonary bypass surgery to support perfusion safety and improve patient outcomes. This new CDI OneView system measures or displays up to 22 vital patient parameters, including oxygen delivery, cardiac index, area under the indexed oxygen delivery curve, oxygen extraction ratio and measured flow.

Additionally in August 2024, LivaNova received the FDA 510(k) clearance and CE mark for its Essenz in-line blood monitor. Essenz ILBM provides accurate and continuous measurement of essential blood parameters throughout cardiopulmonary bypass (CPB) procedures, according to LivaNova. It integrates into the next-generation Essenz perfusion system. Essenz enables perfusionists to access and manage reliable blood parameters directly from the system's cockpit. It eliminates the need for additional monitors or holders.

Geographical Analysis

North America is expected to hold a significant position in the In-line blood monitoring devices market share

North America is expected to hold the largest market share in the global In-line blood monitoring devices market. The increasing prevalence of chronic diseases and the rising number of cardiac surgeries driving the in-line blood monitoring devices market. The use of in-line monitoring devices in operating rooms for cardiac bypass surgeries is a crucial factor in the healthcare landscape of North America. With a substantial number of Coronary Artery Bypass Grafting (CABG) procedures performed annually, the demand for advanced monitoring technologies is essential for ensuring patient safety and enhancing surgical outcomes.

For instance, as per ScienceDirect research in June 2024, the average total cardiac surgical volume across 24 countries with available data was 123.2 surgeries per 100,000 population per year. This figure varies significantly by country, with South Korea reporting a low of 27.3 surgeries per 100,000 and the United States exhibiting the highest rate at 271.5 surgeries per 100,000. This increasing surgery number demands in-line blood monitoring devices in the U.S. market.

The increasing prevalence of cardiovascular diseases is driving the need for advanced monitoring devices during surgical interventions. As a greater number of patients undergo surgeries that involve cardiopulmonary bypass, there is a demand for dependable in-line blood monitoring devices.

For instance, according to the Centers for Disease Control and Prevention (CDC), cardiovascular disease remains the leading cause of death for both men and women across various racial and ethnic groups in the United States. In 2022, around 702,880 individuals lost their lives to heart disease, which translates to approximately 1 in every 5 deaths. With a person succumbing to cardiovascular disease every 33 seconds, there is an urgent need for prompt and precise medical interventions in clinical environments. The implementation of continuous blood monitoring can significantly enhance patient outcomes during critical surgical procedures.

Asia-Pacific is growing at the fastest pace in the In-line blood monitoring devices market

The Asia-Pacific region is experiencing the fastest growth in the In-line blood monitoring devices market. The increasing number of bypass surgeries and heart-lung transplants in the Asia-Pacific region is a significant driving factor for the in-line monitoring devices market indicating an increasing demand for surgical interventions aimed at treating severe cardiovascular diseases. As more patients undergo these procedures, there is a corresponding need for effective in-line monitoring devices that can continuously track vital signs, including heart rate, blood pressure, oxygen saturation, and other critical parameters during surgery.

The increase in Coronary Artery Bypass Grafting (CABG) procedures in India signifies a growing demand for effective cardiac interventions. As more patients undergo CABG, the need for reliable in-line blood monitoring devices becomes crucial to ensure patient safety and optimize surgical outcomes. Continuous monitoring of vital parameters such as blood pressure, heart rate, and oxygen saturation is essential during these complex surgeries.

For instance, according to the Times of India (TOI), the increase in bypass surgeries among patients in their early to mid-30s by 30% over the past decade, with an annual rise of 5%, is a significant driving factor for the in-line blood monitoring devices market. This trend reflects a concerning shift in cardiovascular health, indicating that heart attacks and related diseases are becoming more prevalent in younger individuals.

Additionally, according to the Journal of the Practice of Cardiovascular Sciences, in India, 1,328 heart transplants, 475 lung transplants, 128 Left Ventricular Assist Device (LVAD) implants, and 61 lung transplants for COVID-19 lung disease completed by March 2023, highlights significant advancements in the field of organ transplantation. The annual figures show a steady number of procedures, with 129 lung transplants performed in 2023 and 62 in 2024 up to July, alongside 102 heart transplants in 2023 and 62 in 2024 until July. This upward trend in complex surgical procedures is a crucial driver for the inline monitoring devices market in the region.

Competitive Landscape

The major global players in the In-line blood monitoring devices market include Terumo Corporation, LivaNova PLC, Eurosets S.r.l. and Spectrum Medical Ltd.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global In-line blood monitoring devices market report delivers a detailed analysis with 44 key tables, more than 48 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.